These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 32310714)
1. A Comparative Ocular Pharmacokinetics Study of Preservative-Free Latanoprost Unit-Dose Eye Drops and a Benzalkonium Chloride-Preserved Branded Product Following Topical Application to Rabbits. Zhou T; Miao Y; Li Z; Lu P; Liang Z; Yang J; He J; Xia H; Zhang Z; Zhang J J Ocul Pharmacol Ther; 2020 Sep; 36(7):522-528. PubMed ID: 32310714 [No Abstract] [Full Text] [Related]
2. Pharmacokinetics and Pharmacology of Latanoprost 0.005% without Benzalkonium Chloride Vs Latanoprost 0.005% with Benzalkonium Chloride in New Zealand White Rabbits and Beagles. Halder A; Khopade AJ Curr Eye Res; 2021 Jul; 46(7):1031-1037. PubMed ID: 33719796 [No Abstract] [Full Text] [Related]
3. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models. Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995 [TBL] [Abstract][Full Text] [Related]
4. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Pellinen P; Lokkila J Ophthalmic Res; 2009; 41(2):118-22. PubMed ID: 19147999 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes. Sekine Y; Shimada M; Satake S; Okubo M; Hisaka A; Hara T; Honjo M; Aihara M J Ocul Pharmacol Ther; 2018 Apr; 34(3):280-286. PubMed ID: 29323612 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Ocular Toxicity Evaluation of Latanoprost Ophthalmic Solution, 0.005%, with Preservative Level Reduced to Below the Limit of Quantitation. Venkatesh S; Richardson M J Ocul Pharmacol Ther; 2023 Nov; 39(9):622-630. PubMed ID: 37582270 [No Abstract] [Full Text] [Related]
7. Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops. Inoue D; Mohamed YH; Uematsu M; Kitaoka T Cutan Ocul Toxicol; 2020 Jun; 39(2):158-164. PubMed ID: 32295438 [No Abstract] [Full Text] [Related]
8. Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients. Kestelyn PA; Kestelyn PG; De Bacquer D; Stevens AM Int Ophthalmol; 2019 Jan; 39(1):105-109. PubMed ID: 29274019 [TBL] [Abstract][Full Text] [Related]
9. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Kahook MY; Noecker RJ Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664 [TBL] [Abstract][Full Text] [Related]
10. Comparing the effect of benzalkonium chloride-preserved, polyquad-preserved, and preservative-free prostaglandin analogue eye drops on cultured human conjunctival goblet cells. Hedengran A; Freiberg J; May Hansen P; Boix-Lemonche G; Utheim TP; Dartt DA; Petrovski G; Heegaard S; Kolko M J Optom; 2024; 17(1):100481. PubMed ID: 37788596 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Sirolimus Eye Drops Following Topical Ocular Administration in Rabbits. Lin J; Lu Z; Wang Y; Zhang J; Guo J; Huang Y; Lin B; Yang W J Ocul Pharmacol Ther; 2023 Dec; 39(10):735-743. PubMed ID: 37579189 [No Abstract] [Full Text] [Related]
12. Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey. Savinainen A; Prusakiewicz JJ; Oswald J; Spencer E; Lou Z; Cohen ML; Rashidzadeh H; Josiah S Exp Eye Res; 2019 Dec; 189():107836. PubMed ID: 31626797 [TBL] [Abstract][Full Text] [Related]
13. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension. Aptel F; Choudhry R; Stalmans I Curr Med Res Opin; 2016 Aug; 32(8):1457-63. PubMed ID: 27310103 [TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Kahook MY; Noecker R Adv Ther; 2008 Aug; 25(8):743-51. PubMed ID: 18670744 [TBL] [Abstract][Full Text] [Related]
15. Formulation effects on ocular absorption of brimonidine in rabbit eyes. Acheampong AA; Small D; Baumgarten V; Welty D; Tang-Liu D J Ocul Pharmacol Ther; 2002 Aug; 18(4):325-37. PubMed ID: 12222763 [TBL] [Abstract][Full Text] [Related]
16. Comparison of human ocular distribution of bimatoprost and latanoprost. Ichhpujani P; Katz LJ; Hollo G; Shields CL; Shields JA; Marr B; Eagle R; Alvim H; Wizov SS; Acheampong A; Chen J; Wheeler LA J Ocul Pharmacol Ther; 2012 Apr; 28(2):134-45. PubMed ID: 22136089 [TBL] [Abstract][Full Text] [Related]
17. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Whitson JT; Cavanagh HD; Lakshman N; Petroll WM Adv Ther; 2006; 23(5):663-71. PubMed ID: 17142200 [TBL] [Abstract][Full Text] [Related]
18. Ocular pharmacokinetics profile of different indomethacin topical formulations. Bucolo C; Melilli B; Piazza C; Zurria M; Drago F J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system. Ryan G; Fain JM; Lovelace C; Gelotte KM BMC Ophthalmol; 2011 Apr; 11():8. PubMed ID: 21510881 [TBL] [Abstract][Full Text] [Related]
20. Ocular and systemic pharmacokinetics of latanoprost in humans. Sjöquist B; Stjernschantz J Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S6-12. PubMed ID: 12204697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]